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Summary.-Plasma CEA values and serum y glutamyl transpeptidase activities
have been compared in control subjects and 109 patients with colorectal carcinoma
and 35 with non-malignant hepatic disease. CEA values alone differentiate hepatic
metastases from non-malignant hepatic disease with a high degree of certainty.
While CEA may be elevated with metastases, irrespective of site, yGT is elevated
mainly in association with hepatic metastases. The combination of CEA and yGT
is helpful in identifying hepatic metastases and in their differentiation from local
recurrences or metastases to other sites.
THERE HAVE BEEN several publications
describing initial experiences in the use of
plasma carcinoembryonic antigen (CEA)
levels in the detection of gastrointestinal
cancer in clinical practice (Gold and
Freedman, 1965; Lo Gerfo et al., 1972;
Zamcheck et al., 1972). There is, how-
ever, growing evidence that plasma CEA
may be increased in a wide spectrum of
malignant and non-malignant disease
(Laurence et al., 1972; Lo Gerfo, Krypey
and Hansen, 1971); this has been the
subject of a recent review (Laurence and
Munro Neville, 1972).
Furthermore, although very high
values of CEA strongly suggest extensive
hepatic metastases in patients with gastro-
intestinal cancer, these results are more
variable in early disease. It seems un-
likely, however, that any single test will
enable accurate differentiation of the
stage of the disease in individual patients
and thus combinations of tests have been
used. Aronsen, Nosslin and Pihl (1970)
suggested that a multiparametric dis-
criminant analysis based on serum y
glutamyl transpeptidase (yGT), alkaline
phosphatase, alanine aminotransferase and
bilirubin can achieve a 9300 correct
diagnosis of liver involvement by cancer.
Other authors suggest that yGT alone is
of similar value and is indeed the pre-
dominant factor in this analysis (Delarue
et al., 1973; Huguet and Azzopardi,
1970). However, Baden et al. (1971)
were not convinced that yGT alone, or
the combination of yGT and alkaline
phosphatase, was reliable in the detection
of hepatic metastases.
The use of combinations of CEA and
other tests has not hitherto been reported.
In this paper we describe the use of
combinations of plasma CEA and serum
yGT for the detection of metastatic
colorectal cancer and for distinguishing
the sites of the metastases.
Reprint iequests to L. Steele, Department of Experimental Pathology an(1 Cancer Research, University
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MATERIALS AND METHODS
Plasma CEA and serum yGT levels were
measured in 60 patients Mwith primary
tumours of the colon or rectum and in 49
with metastatic colorectal cancer, in 17 of
whom the primary tumour was also present.
Similar measurements were made in 35
patients with histologically proven acute
hepatitis, chronic hepatitis or cirrhosis.
Normal values for plasma CEA were derived
from measurement of samples from 42
members of the staff of the Chester Beatty
Institute who were over the age of 40 years.
Normal values for yGT were obtained from
a study of 67 healthy blood donors aged
between 20 and 63; there was no age or
sex related variation of the values.
TABLE I
CEA yGT
(ng/ml) (i.u./1)
458 155
115 147
163 279
945 487
63
110 18
280 72
300 96
1200 800
285 19
655 49
1020 65
11 *7
12-,3 24
36-5 17
53 - 0 46
105- 5 46
116 5
97
225 78
1040 85
1190 219
metastases
Clinical status of
patient
Primary tumour
NT
Clinical suspicion of
enlarged liver
Liver metastases (pro-
gressive enlarge-
ment)
NT
NT
NT
NT
Liver metastases conI-
firmed by scan
Primary tumour
Liver scan negative
? Liver enlarged
Liver metastases con-
firmed by scan
2 no(lules in liver seen
at operation
NT
NT
NT
Liver metastases con-
firmed by scan
NT
Liver enlarged
Liver metastases con-
firmed by scan
All patients were questioned about recent
consumption of alcohol as it is well known
that ingestion of alcohol causes a temporary
rise of yGT (Rollason, Pincherle and Robin-
son, 1972; Rosalki and Rau, 1972) and
possibly CEA (Delwiche, Zamcheck and
Harcon, 1973). Any patient who had taken
alcohol within 24 h was excluded. This
necessitated ignoring only 2 results.
At the time of surgery the extent of
disease was assessed by careful inspection
and palpation. Liver scans were undertaken
only ifthere was reason to suspect metastases
but there had been no evidence of hepatic
metastases at laparotomy. Metastasis to the
liver was accepted if lesions were seen at
laparotomy or if there was progressive
enlargement of the liver with palpable
nodules. Direct extension of the tumour to
the pelvis and peritoneum was determined
either at laparotomy or by clinical examina-
tion at follow up.
As our preliminary studies had shown
considerable variations of yGT levels during
the immediate post-operative period, no
samples were taken until 8 weeks after
surgery.
All enzyme estimations were carried out
using a Unicam AC 62 enzyme programmer
with an SP 1800 spectrophotometer. Gamma
glutamyl transpeptidase (E3, 2.3.2. 1.) was
assayed by a modification of the method
of Jacobs (1971): 0-12 ml of serum was
mixed with 1-5 ml, 6-3 mmol glycyl-glycine
(BDH), the reaction was started with 2-0 ml
saturated Ly-glutamyl-p-nitroanilide (Sigma)
and the release of p-nitroanilide monitored
continuously for 6 min. Results are ex-
pressed in International Units per litre
(i.u./l).
For CEA, 10 ml of venous blood was
collected into a tube containing 12 mg of
dipotassium EDTA. After mixing, the plas-
ma was separated within 2 h of collection
and stored at -20°C. Samples were trans-
ported packed in solid carbon dioxide.
CEA was measured at the Chester Beatty
Research Institute, using a modification
(Laurence et al., 1972) of the double antibody
radioimmunoassay system of Todd (Egan et
al., 1972), and the results expressed in
ng/ml.
RESULTS
CEA values for controls, various stages
of colorectal cancer and non-malignant
Time
after
surgery
(months)
Patient 1
0
2
3
5
Patient 2
4
6
9
10
14
(15)
Patieint 3
0
2
6
Patienit 4
0
2
5
8
8
8
10
Patient 5
16
22
23
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Control
A
Mean s.d.
CEA 1- 0864 0-1513
(42)
yGT 1-0916 0 2085
(67)
TABLE II
Primary
P* Mean s.d.
<0 0005 1-3997 0 4460
(43)
<0*0005 1-2835 0 2698
(43)
Liver metastases
Pt Mean s.d.
<0*0005 2-7423 0-9211
(31)
<0*0005 2 0507 0-4107
(31)
All tests performed on the logarithms of the experimental values.
* Significance of mean between controls and primary tumours.
t Significance of mean between primary tumours and hepatic metastases.
Both using Student's " t " test.
Figures in parentheses indicate the number of observations in each category.
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Fia. 1. Distribution of CEA values plottedl on a logarithmic scale for: (a) 42 controls; (b) 43 patients
with primary colorectal cancer not extending beyond the regional lymph nodes of the bowel;
(c) 6 patients with primary colorectal cancer extending into the pelvis; (d) 12 patients who de-
veloped recurrent tumour in the pelvis or peritoneum following the resection of a primary tumour;
(e) 11 patients with involvement of the liver at the time of resection of the primary tumour (Q)
or some time after resection of the primary tumour (0); (f) 35 patients with actute or chronic
cirrhosis or hepatitis.
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FIG. 2.-Relation of yGT and CEA in primary colorectal cancer without metastatic spread (x),
with local extension into the pelvis (A) and with metastatic involvement of the liver (A). Values
are plotted on a logarithmic scale.
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FIG. 3. Relation of yGT and CEA in metastatic colorectal cancer with (-) and without (O) in-
volvement of the liver. Values are plotted on a logarithmic scale.
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hepatic disease are shown in Fig. 1. The
normal value for CEA, as measured by
our method, is 129 + 40ng/ml. Thereis
considerable overlap between the disease
groups. Figure 2showsCEAplottedagainst
yGTin patients presenting with primary
colorectal cancers. We have arbitrarily
adopted a discriminant level ofCEA of100
ng/ml and a discriminant level ofyGTof45
i.u./l. NormalyGT values are 139 ± 77
i.u./l. Using these discriminants, it can be
seen that 37 out of43 tumours without evi-
dence of spread outside the bowel and
its local lymph nodes or distant metastasis
fall within the area bounded by the discri-
minants.
When hepatic metastases or local
extension outside the bowel involving the
peritoneum or pelvis were present, 14 out
of 17 tumours had values on or outside
the area bounded by the discriminants.
In Fig. 3 the distribution of values is
shown in patients who developed local
recurrent tumour in the pelvis or hepatic
metastases after a variable period (6
months-8 years) ofbeing clinically tumour
free. Using CEA alone and a discrimi-
1000r
b GLUTAMYL
TRANSPEPTIDASE
(Iu/I)
100 -
I0
nant value of 100 ng/ml, there were 3 pati-
ents out of 20 with liver metastases who
would not have been detected. However,
using both parameters 20 out of 20 would
havebeendetectedandonly 5of12patients
with local extension in the abdomen would
have beenthoughtwronglyto have hepatic
metastases.
Considering both those patients who
presented with hepatic metastasis after
the primary tumour had been resected
and those in whom there was a primary
and also coincidental metastases in the
absence of non-malignant hepatic disease,
then the combined CEA above 100 ng/ml,
particularly after excision of the primary,
is frequently, but not invariably, asso-
ciated with hepatic metastases. Using
both these tests, it is possible to detect
the presence of clinically inapparent
tumour in the liver before laparotomy or
during follow up with a useful degree
of certainty. In the interpretation of
abnormal yGT and CEA values it is, of
course, important to exclude other causes
of raised values, such as pancreatic
disease or recent intake of alcohol, but
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FIG. 4. Relation of yGT ancd CEA in cirrhosis ancl hepatitis (-+-) compared with metastatic involve-
ment of the liver by coloiectal cancer (*). Values are plotted on a logarithmic scale.
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fortunately these were rarely seen in the
group under study.
There would appear to be two advan-
tages offered by using this combination
of tests. First, it may be helpful when
the clinician is faced with a patient with
hepatomegaly after a long disease-free
interval following the excision of a colonic
or rectal cancer. The yGT indicates that
the liver is diseased and the CEA value
appears to discriminate between hepato-
megaly due to metastatic cancer and
benign hepatic disease with a high degree
of certainty. Secondly, when used fre-
quently during the surveillance ofpatients
after excision ofcolorectal cancer, changes
of levels of CEA and yGT may prove to
be a very early indication that there are
metastases in the liver. Long-term
studies, the preliminary results of which
indicate that these tests may be abnormal
for 3-9 months before hepatic metastases
are confirmed clinically, are now in
progress. At present, the response of
advanced metastatic colorectal cancer to
chemotherapy is frequently disappointing
(Moeitel, 1973) but these tests might
provide an improvement in the outlook
for such patients by allowing treatment to
be given at an earlier stage.
Although the simple combination of
these 2 tests provides good discrimination
between the various stages of disease in
patients with colorectal cancer, not all
patients are classified correctly. It seems
likely that the use of additional, carefully
selected, parameters will improve discri-
mination further and will be of assistance
both in early diagnosis and in monitoring
the effects of treatment.
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